Beyond Viral Suppression: Predictors of HBV Outcomes, Cure Potential, and HCC Risk

Nov 10 2025
Convention Center: Room 207, Level 2
5:00 PM - 6:30 PM

World Class Speakers

Arpan Mohanty, MBBS, MSc
Moderator

Arpan Mohanty, MBBS, MSc

Boston University Chobanian and Avedisian School of Medicine
Grace Lai-Hung Wong, MD, MBChB (Hons), FRCP, FHKCP, FHKAM
Moderator

Grace Lai-Hung Wong, MD, MBChB (Hons), FRCP, FHKCP, FHKAM

The Chinese University Of Hong Kong

Description

This session will explore how clinical and molecular markers can inform prognosis and therapeutic strategy in chronic hepatitis B. Presentations will compare the impact of current antiviral therapies on hepatocellular carcinoma (HCC) risk and examine how partial virologic responses and HBsAg decline correlate with long-term outcomes. The session will also address the evolving role of therapy discontinuation in HBeAg-negative patients, the utility of quantitative HBsAg and HBV RNA in distinguishing inactive carriers from those with partial cure, and the predictive value of biomarkers in selecting candidates for functional cure.

Journey Maps

Objectives

  • Compare the effects of different antiviral regimens on HCC risk and assess the prognostic implications of partial HBsAg decline
  • Describe the clinical role of HBV RNA and quantitative HBsAg in distinguishing carriers, monitoring therapy, and evaluating cure potential.
  • Evaluate strategies such as treatment discontinuation in HBeAg-negative patients and the role of host immune remodeling in functional cure